Q-omics provides the consensus-scored CATSPERZ profile across patient tissues and cancer cell-line models. CATSPERZ expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CATSPERZ is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CATSPERZ RNA expression shows 11,932 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, HNSC, and UVM as cancer lineages where CATSPERZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CATSPERZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CATSPERZ survival associations across molecular data types. CATSPERZ RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CATSPERZ RNA expression–survival associations across cancer types. High CATSPERZ expression shows unfavorable associations in THCA, ACC, UCEC, READ and MESO, but favorable associations in LGG. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify THCA as the clearest survival context for CATSPERZ RNA expression.
This table summarizes CATSPERZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CATSPERZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CATSPERZ shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LIHC, LUAD and PAAD. The HNSC box plot shows higher CATSPERZ RNA expression in tumor versus normal tissue (log2 FC = +0.121, t-test p < 0.001).
This table shows molecular features associated with CATSPERZ in patient tissues and cancer cell lines. In patient samples, CATSPERZ shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CATSPERZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
